Table 3.
Association of Chronic OXAIPN with Baseline and Clinical Variables
| variable | Total no. of patients;N=228(%) | Chronic OXAIPN | P value | ||
|---|---|---|---|---|---|
| No;n=98(%) | Yes;n= 130(%) | ||||
| Age | |||||
| Median 53 | ≤53 | 122 (53.5) | 45 (45.9) | 77 (59.2) | 0.06 |
| >53 | 106 (46.5) | 53 (54.1) | 53 (40.8) | ||
| Gender | |||||
| Male | 142 (62.3) | 61 (62.2) | 81 (62.3) | 0.9 | |
| Female | 86 (37.7) | 37 (37.8) | 49 (37.7) | ||
| ECOG-PS | |||||
| 0 | 22 (9.6) | 12 (12.2) | 10 (7.7) | 0.75 | |
| 1 | 175 (76.8) | 72 (73.5) | 103 (79.2) | ||
| 2 | 31 (13.6 | 14 (14.3) | 17 (13.1) | ||
| Site of cancer | |||||
| Stomach | 111 (48.7) | 44 (44.9) | 67 (51.5) | 0.2 | |
| Colorectal | 108 (47.4) | 48 (49.0) | 60 (46.2) | ||
| Gall bladder/ | 9 (4.0) | 6 (6.1) | 3 (2.3) | ||
| pancreas | |||||
| Type of chemotherapy | |||||
| Adjuvant | 85 (37.3) | 37 (37.8) | 48 (36.9) | 0.75 | |
| Neoadjuvant | 30 (13.2) | 11 (11.2) | 19 (14.6) | ||
| Palliative | 113 (49.5) | 50 (51.0) | 63 (48.5) | ||
| Type of regimen | |||||
| CAPOX | 123 (53.9) | 46 (46.9) | 77 (59.2) | 0.1 | |
| EOX | 76 (33.3) | 34 (34.7) | 42 (32.3) | ||
| FOLFOX | 20 (8.8) | 12 (12.3) | 8 (6.2) | ||
| GEMOX | 9 (4.0) | 6 (6.1) | 3 (2.3) | ||
| Median dose 780mg/m2 | |||||
| <780 | 90 (39.5) | 53 (54.1) | 37 (28.5) | 0.0001 | |
| ≥780 | 138 (60.5) | 45 (45.9) | 93 (71.5) | ||
* p value <0.05 is statistically significant;ECOG-PS, Eastern Cooperative Oncology Group Performance Status;BSA: Body Surface Area